BISOT-2.5MG TAB
₹131.00
BISOT 2.5mg Tablet is a prescription medication combining Bisoprolol (2.5 mg), a beta-blocker, and Telmisartan (40 mg), an angiotensin II receptor blocker (ARB). This combination is primarily used to manage hypertension (high blood pressure) by reducing heart rate and relaxing blood vessels, thereby lowering blood pressure and decreasing the risk of cardiovascular events.
Description
Composition:
-
Bisoprolol (2.5 mg): A beta-1 selective adrenergic blocker that decreases heart rate and myocardial contractility, reducing cardiac output.
-
Telmisartan (40 mg): An angiotensin II receptor blocker (ARB) that relaxes blood vessels, leading to vasodilation and reduced peripheral resistance.
Uses:
-
Hypertension (High Blood Pressure): Effective in lowering blood pressure in patients not adequately controlled with monotherapy.
-
Cardiovascular Risk Reduction: Helps in reducing the risk of heart attacks and strokes by maintaining optimal blood pressure levels.
Dosage and Administration:
-
Dosage: As prescribed by a healthcare professional, typically one tablet daily.
-
Administration: Should be taken at the same time each day, with or without food. Swallow the tablet whole; do not crush or chew.
Side Effects:
Common side effects may include:
-
Headache
-
Dizziness
-
Fatigue
-
Cold extremities (hands/feet)
-
Bradycardia (slow heart rate)
-
Numbness of extremities
-
Decreased blood pressure
-
Increased potassium level in blood
Precautions:
-
Alcohol: Avoid consumption, as it may enhance hypotensive effects.
-
Pregnancy and Breastfeeding: Not recommended during pregnancy, especially in the second and third trimesters, as it may harm the fetus. Consult your doctor for safer alternatives. Use only if prescribed by a doctor during breastfeeding, as safety data is limited.
-
Driving and Operating Machinery: Exercise caution, as the medication may cause dizziness or fatigue.
-
Kidney and Liver Impairment: Dose adjustments may be necessary; consult a healthcare provider.







Reviews
There are no reviews yet.